期刊文献+

糖尿病并发症的药物治疗 被引量:20

Development of Drugs for Treatment of Diabetic Complication
暂未订购
导出
摘要 糖尿病并发症对人类健康造成极大危害 ,针对各种糖尿病并发症的病因开发其治疗药物已成为人们关注的热点 ,并取得可喜进展。本文分类概述糖尿病并发症治疗药物的作用机制、临床应用及疗效研究 ,其药物包括醛糖还原酶抑制剂、糖基化终产物抑制剂。 Diabetic complication is a disease threatening health. The development of drugs targeting different cause of the disease has been widely concerned. In t his article, the acting mechanisms, clinical applications and efficacies of thes e drugs, which include aldose reductase inhibitors, AGE inhibi tors, antioxidants, ACE inhibitor, etc., were introduced classifiedly.
作者 赵晶 戴德哉
出处 《药学进展》 CAS 2003年第2期88-91,共4页 Progress in Pharmaceutical Sciences
关键词 糖尿病 并发症 药物治疗 醛糖还原酶抑制剂 糖基化终产物抑制剂 抗氧剂 血管紧张素转换酶抑制剂 Diabetic complication Aldose reductase inhibitor AGE inhibitor Antioxidant ACE inhibitor
  • 相关文献

参考文献14

  • 1陈亮,杨华章.糖尿病口服药物治疗进展[J].国外医学(内分泌学分册),2000,20(3):140-143. 被引量:26
  • 2Nathan D M. Long-term complications of diabetes mellitus[J]. N Engl J Meg, 1993, 328(23) : 1676-1681.
  • 3Gabbay K H. The sorbitol pathway and the complications of diabetes[J]. N Eagl J Meg, 1973, 288(16) : 831-836.
  • 4Jaspan J B, Towle V L. Clinical studies with an aldose reduc-tase inhibitor in the autonomic and somatic neuropathies of di-abetes[J]. Metabolism, 1986, 35(Suppl, 1): 83-92.
  • 5Foppiano M, Lombardo G. Worldwide pharmacovigiiance systems and tolrestat withdrawal[J]. Lancet, 1997, 349(9049): 399-400.
  • 6Greene D, Arezzo J, Brown M. Dose-related effects of the aldose reductase inhibitor zenarestat on nerve sorbitol levels,nerve conduction velocity and nerve fiber density in human diabetic neuropathy[J]. Diabetes, 1996, 45(Suppl, 2): 9-12.
  • 7Oates P J, Ellerly C A. Reversal of galactose-induced renal hyperperfusion in rats by aldose reductase inhibitor zopolre-stat[J]. Diabetologia, 1999, 42(Suppl, 1): Abst 1034.
  • 8Pfeifer M A, Schumer M P, Gelber D A. Aldose reductase inhibitors: the end of an era or the need for different trial de-signs[J]?Diabetes, 1997, 46(Suppl, 2) : S82-89.
  • 9Schmidt A M, Yan S D, Wautier J L, et al. Activation of receptor for advanced glycation end products. A mechanism for chrionic vascular dysfunction in diabetic vasculopathy and atherosclerosis[J]. Circ Res, 1999, 84(5): 489-497.
  • 10Baynes J W, Thorpe S R. Role of oxidative stress in diabetic complications. A new perspective on an old peredigm[J]. Di-abetes, 1999, 48(1): 1-9.

二级参考文献15

  • 1Owens DR.Repaglinide-prandialglucose regulator:a new class of oral antidiabetic drugs 〔J〕.Diabet Med,1998,15(Supp14):S28~S36.
  • 2John R.White Jr,Pharm D.The Pharmacological reduction of blood glucose in patientswith type 2 diabetes mellitus 〔J〕.Clin Diabet,1998,16:2~4.
  • 3BalfourJA,FauldsD.Repaglinide〔J〕.DrugsAging,1998,13:173-180.
  • 4Lefebvre PJ,Scheen AJ.The postprandial state risk of cardiovascular disease 〔J〕.DiabetMed,1998,15(Supp1 4):S63~S68.
  • 5Hatorp V,Huang WC,Strange P.Pharmacokinetic profiles of repaglinide in elderlysubjects with type 2 diabetes 〔J〕.J Clin Endocrinol Metab,1999,84:1475~1478.
  • 6Hatorp V,Oliver S,Su CA.Biavailability of repaglinide,a novel antidiabeticagent,administered orally in tablet or solution form or intravenously in healthy malevolunteers 〔J〕.Int J Clin Pharmacol Ther,1998,36:636~641.
  • 7Chetty DJ,Chien YW.Novel methods of insulin delivery:an update 〔J〕.Crit RevTher Drug Carrier Syst,1998,15:629~670.
  • 8Saudek CD.Novel forms of insulin delivery 〔J〕.Endocrinol Metab Clin NorthAm,1997,26:599~610.
  • 9Kimura T,Sato K,Sugimoto K,et al.Oral administration of insulin as poly (vinylalcohol)-gel spheres in diabetic rats 〔J〕.Biol Pharm Bull,1996,19:897~900.
  • 10Foley JE.Rationale and application of fatty acid oxidation inhibitors in treatmentof diabetes mellitus 〔J〕.Diabetes Care,1992,15:773~784.

共引文献25

同被引文献198

引证文献20

二级引证文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部